Todd Krueger came to AOBiome with 20+ years of experience in healthcare strategy, business development, operations and finance. He most recently led commercial efforts for the genomics platform at the Broad Institute and has held senior positions at Claritas Genomics and Life Technologies. He has also been involved in the founding of several biotech startups, including Gynesonics, Nodality, and Anestis Therapeutics. In 1999 he co-founded Fluidigm Corporation (NASDAQ: FLDM), serving as CFO and Vice President of Business Development. He also serves on the Board of Directors of several companies, including General Automation Laboratory Technologies (GALT), a microbiome tools startup. He started his career as a consultant for Bain and Company in Boston.
Mr. Krueger graduated Highest Distinction from Northwestern University with a degree in Economics and earned his MBA from the Kellogg School of Management.
Chief Medical Officer
Larry Weiss MD is the Chief Medical Officer at AOBiome. He has an extensive background in natural products chemistry, microbiology, clinical medicine, and pharmaceutical development and product commercialization. Dr. Weiss is board certified in Anesthesiology, has an MD from Stanford University Medical School, and a BS from Cornell University in Biochemistry. He has a multiple patents and is published in the areas of chemistry, electrophysiology, pharmacology, and microbiology. Dr. Weiss is the founder of CleanWell Company.
Head of Theraputics, Co-Founder
Spiros Jamas is a biotech entrepreneur with over 20 years of senior management experience in the biopharmaceutical industry. He has served as CEO and/or founder of several innovation-driven companies in immunology, anti-virals, antibiotics and carbohydrate-based therapies (Tempero, Enanta Pharmaceuticals, Alpha-Beta Technology, Inc.). In these capacities he has assembled high-performance teams, raised $300M in funding, and led R&D programs from discovery research to advanced clinical development.
Recently, Dr. Jamas was the co-founder, President and CEO of Tempero Pharmaceuticals, a GlaxoSmithkline-funded company targeting T-cell mediated diseases. Prior to joining Tempero, he was the Global Healthcare Analyst for State Street Global Advisors (SSGA), the world's second largest asset management firm with over $1 trillion in assets under management.
Dr. Jamas obtained a Doctor of Science in Biotechnology and an MS from MIT and a BS in Chemical Engineering from UMIST, England. He is an author and co-inventor on numerous papers and patents.
Ramesh Ratan joined AOBiome as Chief Financial Officer with more than 35 years of experience in senior or executive vice president finance and operations positions at companies developing innovative biomedical technologies. He has held positions at Bristol-Myers Squibb, Xcellerex, Inc., Enanta Pharmaceuticals, Repligen Corp., and at technology companies such as American Superconductor Corporation and Equinox Solutions, Inc. He has been instrumental in raising over $150 million and negotiating numerous corporate alliances. Mr. Ratan continues to serve as CFO and Corporate Secretary at ABOVE Solutions Inc.
Chief Operating Officer
Lauren Ambrogio joined the team in May of 2016, overseeing AOBiome's Research and Operational efforts. Prior to AOBiome, she was Chief Operating Officer at Q-State Biosciences where she provided leadership and oversight for a successful, fast-growing biotechnology start-up. In addition to her most recent roles, Ms. Ambrogio has held several management positions over the last 10 years merging her love for cutting-edge science and technology with operational excellence, including roles at the Dana Farber Cancer Institute, the Broad Institute, and Claritas Genomics. She brings expertise in genomics, project and portfolio management, product development, and corporate operations to the AOBiome team.
Ms. Ambrogio is an author on numerous scientific papers, holds a BS in Molecular Genetics from the University of Rochester, and is a Certified Project Management Professional.
Inventor and Founder
David Whitlock is the Inventor and co-founder of AOBiome. His initial discovery that Ammonia Oxidizing Bacteria could be reintroduced to the human microbiome formed the scientific basis for AOBiome's efforts. Mr. Whitlock holds both an MS and a BS in Chemical Engineering from MIT and is the author or co-author of several key patents in the field.
Chairman and Founder
An MIT-trained mechanical engineer, Jamie entered the field of translational medicine when his 29 year old brother Stephen was diagnosed with Motor Neurone Disease(MND)/Amyotrophic Lateral Sclerosis (ALS). Today Jamie is chief scientist and architect for PatientsLikeMe, a patient network that helps improve lives and a real time research platform that advances medicine. Described by CNNMoney as one of the 15 companies that will change the world, Jamie co-founded PatientsLikeMe to ensure patient outcomes become the primary driver of the medical care and discovery process. Jamie is also the founder and past CEO of the ALS Therapy Development Institute (ALS TDI), the world's first non-profit biotechnology company. During his tenure at ALS TDI Jamie helped pioneer an open research model and industrialized therapeutic validation process that made ALS TDI the world's largest and most comprehensive ALS research program. Jamie and his brother were the subject of Pulitzer Prize-winning author Jonathan Weiner's biography His Brother's Keeper and the documentary So Much So Fast.
Dr. Jun Wang , Founder and CEO of iCarbonX. He received B.S. degree in artificial intelligence and Ph.D. in bioinformatics from Peking University. In 1999, Dr. Wang co-founded BGI, which is now widely recognized as one of world's premier research facilities committed to excellence in genome sciences. During this time, Dr. Wang managed three rounds of fund-raising (about 1B$ in total) at BGI, and acquired a U.S. public company: Complete Genomics. He was recognized with numerous awards and nominations, such as His Royal Highness Prince Foundation, and "Fortune's 40 under 40" by Fortune Magazine (2013), "Highly Cited Researchers 2015" by Thomson Reuters.
Chung Wu is co-founder and COO of iCarbonX. Dr. Wu joined the Boston Consulting Group (BCG) in 2003. As the global Partner and Managing Director, Dr. Wu led her team to assist tens of multinational and domestic companies to formulate corporate strategy and improve business management.
Director and Co-Founder
Mr Barshack has been both founding and funding several successful internet startups since 1995, where he co-founded the Bigfoot family of companies. Bigfoot pioneered B2C email services, Bigfoot Interactive was a market leader in B2B in direct e-marketing services. NeoPlanet was another visionary product that created a self contained user environment for all email, chat, and browsing. In 2000, Mr Barshack co-founded Tribeca Tables which was the worlds largest provider of a comprehensive white label ePoker solution to the worlds top gaming brands. Tribeca was acquired in 2006. Prior to 1995, Mr. Barshack served 15 years on wall street in various capacities including a derivatives specialists, equity research analyst, and also a programmer. Mr. Barshack resides in Sun Valley, Idaho with his wife Erin.
Director and Co-Founder
After receiving a BA at Washington & Lee University and, then, his MIA from Columbia University Graduate School of International Relations, specializing in Latin American studies, Hilly has had a varied domestic and international entrepreneurial management experience. He worked in both Latin America and the US for International Basic Economy Corp. (IBEC), which was a company founded by Governor Nelson Rockefeller to assist in the growth of the basic economies of the developing world. He spent four years in Sao Paulo, Brazil and another three years in Santiago, Chile, before returning to the home office in New York. While in New York he had the unique opportunity to join a team put together by Governor Rockefeller to carry out the "Mission to Latin America", commissioned by President Nixon. He served as special assistant to the governor during the two-year mission that concluded with his being a coauthor of the final report submitted to the President. In 1970, he joined the Boston international mergers and acquisition firm, Robert Weaver and Associates, with primary responsibilities for Latin American business formation and relationships. After six years, Hilly struck out on his own and, with his partner, founded EBAC Agricultural Equipment Corp., in upstate New York. He sold the business in 1984 and returned to Boston. By that time, he had assumed full responsibility for the family's agricultural holdings in Georgia, which he continues to serve as CEO today. Meanwhile, in Boston in the mid-1990s, he co-founded Separation Technologies Inc., presently the leader in high volume separation of fine powders, such as fly ash, industrial minerals and agricultural products. STI was successfully sold to Titan USA. Hilly is presently involved, as a co-founder, in an early stage biomedical start-up venture to develop a unique delivery system for nitric oxide in a wide spectrum of applications. Hilly is also actively involved with the Wildlife Conservation Society (WCS), the Sea Education Association (SEA) and the Vineyard Open Land Foundation. Hilly is an avid outdoorsman, sportsman and traveler, who relishes time well spent with his bride, their four children and, at the present, their seven grandchildren.